Magellan Biosciences Revenue and Competitors

North Billerica, MA USA

Location

$50M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Magellan Biosciences's estimated annual revenue is currently $3.9M per year.(i)
  • 0
  • Magellan Biosciences's total funding is $50M.

Employee Data

    00

Magellan Biosciences's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
Director SalesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Magellan Biosciences?

Magellan Biosciences develops advanced instruments, automated systems, point-of-care products, and consumables for biomedical research and clinical diagnostics worldwide. These tools enable scientists and clinicians to produce better, more-reliable results. And improved results help drive better outcomes -- a new understanding of health and disease, earlier, more-accurate diagnoses -- breakthrough discoveries that can lead to novel treatments, new cures -- innovations to enhance life.

keywords:N/A

$50M

Total Funding

N/A

Number of Employees

$3.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Magellan Biosciences News

2022-04-20 - SARS-CoV-2-specific T-cell epitope repertoire in convalescent ...

... acquisition was performed on a FACSCanto system (BD Biosciences). ... The SparkControl Magellan software v.2.2 was used for data...

2022-04-13 - 18 Share Tips – 18 April 2022

Rhythm Biosciences (RHY) ... This wholly owned subsidiary of Magellan Financial Group invests in global equities and global listed...

2010-02-24 - Magellan Biosciences taps former Fenwal CTO Uchida as CEO

Magellan Biosciences Inc. tapped Hiroshi Uchida, the former technology chief for Fenwal Inc., to be its new president and CEO. The Chelmsford, Mass.-based diagnostics firm said Uchida was instrumental in the carve-out of Fenwal from former parent Baxter International (NYSE:BAX) in 2007. The blo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M6-14%N/A
#2
$1.8M10-9%N/A
#3
$1.6M13-7%N/A
#4
$1.3M15-12%N/A
#5
$4.9M24-17%N/A